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doi:10.1Objective: Retrograde transfemoral artery catheterization is the most common way of implanting a percutaneous
aortic valve. But in some cases, this access cannot be used and the subclavian artery access may represent an
alternative to the femoral route, even offering certain advantages. This article describes prosthetic aortic valve
implantation using the subclavian arterial approach and reports the findings.
Methods: The valve prosthesis is a self-expandable, nitinol-based device (CoreValve; Medtronic Inc. Minneap-
olis, Minn). The axillary or subclavian artery was exposed with a small incision. Rapid ventricular pacing was
used to reduce cardiac output while a routine aortic balloon valvuloplasty was performed. Then, an 18F sheath
was inserted into the axillary artery down into the ascending aorta. By using this method, a prosthesis was im-
planted in 17 patients (aged 71  11 years) whose surgical risk was deemed excessive because of severe comor-
bidity and in whom transfemoral catheterization was considered unfeasible or at risk of severe complications.
Results: Subclavian arterial injury did not occur in any patient. The postprocedural aortic valve area increased
from 0.6  0.3 cm2 to 1.44  0.35 cm2. A transient ischemic attack occurred in 1 patient. Two patients experi-
enced transitory brachial plexus deficit. There were no intraprocedural deaths. Two deaths occurred in the 30-day
follow-up period.
Conclusions: This initial experience suggests that subclavian transarterial aortic valve implantation, in selected
high-risk patients, is feasible and safe with satisfactory short-term outcomes. (J Thorac Cardiovasc Surg
2011;141:487-91)Supplemental material is available online.E
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SAortic valve stenosis is the most frequent adult heart valvu-
lar disease in the western world.1 Patients are often high-risk
candidates for open surgery using a heart–lung machine.2
Although surgical valve replacement remains the ‘‘gold
standard’’ treatment, many patients with severe aortic steno-
sis do not undergo surgery for the following reasons: patient
refusal, excessive surgical risk, advanced age, or self-
preference. Prognosis with medical management is poor,
and the percutaneous approach as an alternative to surgery
has been limited to palliative balloon valvuloplasty.3-5
Transcutaneous aortic valve implantation (TAVI) has been
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The Journal of Thoracic and CaHowever, the technical complexity and associated risks
of the antegrade approach limited its development.13,14
The retrograde femoral arterial approach is an adaptation
of the original aortic valvuloplasty technique and is rapidly
spreading worldwide with encouraging results.15 Patient
selection requires a complete study of the different arterial
access points, such as the aorta, aortoiliac, and femoral ar-
teries. However, peripheral artery disease may render iliofe-
moral access difficult or even impossible in some cases.
Retrograde femoral access difficulties, in elderly patients, re-
late to frequently diseased and tortuous femoral and iliac ar-
teries. These obstacles greatly increase the risk of procedure
failure or vascular injury with potentially lethal complica-
tions. This high vascular risk has led to the development
of transapical or subclavian access techniques that have
been recently described in the medical literature.16-18 Both
techniques offer the advantage of avoiding access site
problems and facilitating valve delivery. However, the
transapical approach, requiring thoracotomy, is more
invasive, making it a high-risk procedure in patients with se-
vere respiratory dysfunction. Moreover, several complica-
tions resulting from the introduction of a percutaneous
valve holder through the apex of the left ventricle have
been reported.16
In centers where the medico-surgical approach of this
new technique was effective, using the axillary or subclavian
artery as a second choice after the femoral artery forrdiovascular Surgery c Volume 141, Number 2 487
Abbreviation and Acronym
TAVI ¼ transcutaneous aortic valve implantation
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Sintroducing the device became obvious. In this prospective
study, we describe the implantation technique, procedural
success, and clinical outcome up to 30 days after TAVI using
transaxillary or subclavian access in 17 consecutive patients
who were purposely recruited. Procedures were performed in
4 different French centers between January and September of
2009.MATERIALS AND METHODS
Patients
A prospective, single-arm study was performed, including patients from
4 French centers (CHRU de Lille, n ¼ 7; Lapitie´ Salpe´trie`re, n ¼ 5; CHRU
de Lyon, n¼ 4; and CHRU de Bordeaux, n¼ 1). Patients with severe symp-
tomatic aortic stenosis were referred for a percutaneous procedure because
of multiple comorbidities and excessive surgical risk. The cases were se-
lected following the guidelines of the ‘‘French Sanitary High Authority.’’
Our objective was to evaluate the feasibility, safety, and clinical outcomes
of TAVI via subclavian or axillary artery access of the 18F CoreValve
Revalving System (Medtronic Inc., Minneapolis, Minn). A heart team of
senior interventional cardiologists, cardiac surgeons, and anesthetists for-
mally reviewed patients with a consensus that patients did not have a reason-
able surgical option. Patient preference alone for a percutaneous procedure
was not considered as an acceptable reason for inclusion. Informed consent
was obtained. The operating team always consisted of a cardiac surgeon, an
interventional cardiologist, and, in some institutions, an interventional radi-
ologist. All patients underwent transthoracic echocardiography and iliofe-
moral and coronary angiography. Angiographic computed tomography
scan and echo Doppler were used to assess the diameter and patency of
the right and left subclavian and axillary arteries when iliofemoral arterial
access was considered at high risk of vascular complications. Short seg-
ments of calcified or focal stenosis were not considered exclusion criterion.
Prosthetic Valve System
The CoreValve Revalving System consists of porcine pericardium cut
into a trileaflet pattern mounted on a nitinol frame. The diameter of the aortic
annulus was measured using the transthoracic echocardiography parasternal
long-axis view immediately below the insertion point of the valve leaflets.
Moreover, because the aortic annulus is not circular, computed tomography
scans were used to measure the shortest and longest diameters. Annulus di-
ameters of 20 to 23 mm and 23 to 27 mm were considered appropriate for
26-mm and 29-mm diameter prostheses, respectively. Both valves require
an 18F introducer sheath. An axillary arterial diameter of 6 mm was consid-
ered adequate for implantation.
Patients were premedicated with a loading dose of clopidogrel and aspi-
rin, and intravenously injected with cefazolin 1 g immediately before the
procedure. The procedure was performed in a catheterization laboratory
with operating room-like sterility precautions. A femoral access was used,
and a 5F pigtail catheter was inserted for control angiograms during valve
implantation. Vein access for the temporary pacemaker lead was used for
rapid pacing during valvuloplasty. Heparin (50 U/kg) was administered in-
travenously on completion of vascular access.
The proximal axillary artery was exposed through a small infra- or supra-
clavicular incision. Two 5-0 Prolene continuous purse sutures were placed
on the anterior face of the artery. A 7F sheath was inserted in the middle of
the purses using a percutaneous technique, and the native valve was crossed488 The Journal of Thoracic and Cardiovascular Surgusing a conventional technique that includes a straight wire. After hemody-
namic transvalvular gradient and telediastolic ventricular pressure measure-
ment, a manually preshaped Stiff wire was placed in the ventricular cavity.
The 18F sheath was then carefully inserted (Figure E1), and its progression
was followed using fluoroscopic guidance. An aortic angiography was per-
formed and displayed during the procedure to facilitate subsequent position-
ing of the sheath and prosthesis. The tip of the sheath was positioned in the
upper part of the ascending aorta (Figure 1, A, B). Balloon valvuloplasty was
performed using 22- and 25-mm balloons (Nucleus, NuMED Inc, Hopkin-
ton, NY) for the 26- and 29-mm Medtronic CoreValve prostheses, respec-
tively. After balloon deflation, rapid pacing was stopped and the balloon
catheter was withdrawn. The valve was then advanced and deployed using
repeated fluoroscopic controls. The prosthesis was positioned so that it pro-
truded 4.0 to 8.0 mm out of the calcified native valve leaflets. During pros-
thesis implantation, no rapid pacing was used. A coordinated approach was
used wherein one operator maintained ideal valve positioning by pulling
slowly on the catheter during valve release, while the second operator turned
the release knob that would deliver the valve. Aortic root angiographies
were performed to assess valve position during implantation. After full re-
lease of the valve, a coaxial stiff wire position was maintained in the left
ventricular cavity and a pigtail was advanced to measure the transvalvular
gradient and then removed carefully. Aortic root angiography and echocar-
diography were performed to reassess valve competency, using standard cri-
teria, and to evaluate the aortic regurgitation severity. After procedure
completion, the subclavian arterial access site was surgically closed or re-
paired, when needed, after purse straining (Figure E2), and a control angio-
gram was performed. Patients were then transferred to the intensive care unit
for 24 to 48 hours of observation. Patients continued taking aspirin indefi-
nitely and clopidogrel for 6 months. Clinical follow-up and transthoracic
echocardiograms were performed within 24 hours of the procedure and at
1 and 4 weeks after the device implantation.
RESULTS
Patient Outcome
Valve implantation was attempted in 17 consecutive pa-
tients between January and September of 2009 in the
above-mentioned centers. Complete follow-up was pursued
to conclusion in all 17 patients. Preoperative characteristics
are shown in Table 1. All patients enrolled had severe symp-
tomatic aortic stenosis with a mean transvalvular gradient of
47 13.3 mm Hg. The preprocedural mean aortic valve area
was 0.6 0.3 cm2. The procedure was performed under gen-
eral anesthesia (13 patients) or local anesthesia in combina-
tion with mild sedative-analgesic treatment. The use of
transesophageal echocardiographic guidance was not sys-
tematic and was left to the discretion of the operators. Percu-
taneous placement of the 18F sheath was successful in all
cases. All patients underwent planned open surgical access
site closure. No vascular complications requiring surgical re-
pair was observed. In one patient, because of initially low
valve implantation, secondary migration occurred while try-
ing to reposition the valve. The valve was positioned in the
middle of the ascending aorta, and a second valve was suc-
cessfully implanted using the same subclavian access.
Prosthesis implantations were uneventful in this small
series. The 2 patients who had undergone operation via
a supraclavicular incision presented minor and transitory
neurologic arm deficit that recovered before patient dis-
charge. One patient had a transient ischemic attack, andery c February 2011
FIGURE 1. Angiogram sheath views in the subclavian and axillary arteries (A) and ascending aorta (B).
Modine et al Evolving Technology/Basic Science1 patient had retrograde aortic dissection during guide wire
insertion. The dissection had healed by the end of the proce-
dure once the subclavian artery was repaired. There were no
intraprocedural deaths. Intraoperative and postoperative
details are shown in Tables 2 and 3.E
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Paravalvular leak, as assessed by angiography and echo-
cardiography controls, was trivial (grade 0–1) in most cases
(n¼ 14). There was no severe postprocedural aortic regurgi-
tation (grade  3).
Valve function, as assessed by echocardiography within
24 hours after implantation, before discharge, and at 1
month, remained essentially unchanged (Table 4). In 2
patients, moderate paravalvular leak occurred immediately
after valve implantation, which seemed to be caused by an
insufficiently expanded frame. Additional valvuloplastyTABLE 1. Baseline characteristics
Age, y, mean ± SD 71 ± 11 y
Angina, n (%) 0
Heart failure, n (%) 26
NYHA III and IV failure class 40
Syncope, n (%) 13.3
Male gender, n (%) 46.2
Diabetes mellitus, n (%) 20
Coronary heart disease, n (%) 53.3
Porcelain aorta, n (%) 0
Prior bypass graft surgery, n (%) 26.6
Prior angioplasty, n (%) 20
Renal dysfunction,* n (%) 6.6
Logistic euroSCORE predicted mortality, mean  SD,% 34  11
Left ventricle ejection fraction% mean 52  14
NYHA, New York Heart Association; SD, standard deviation. *Estimated glomerular
filtration rate>60.
The Journal of Thoracic and Caafter implantation, with a slightly oversized balloon under
rapid pacing, reduced severe paravalvular insufficiency to
trivial in both cases without apparent damage to the valve
leaflets, the lack of which was assessed by the absence of
a central leak during the echocardiographic control. At 30
days and the last day of follow-up, the mean paravalvular
leak remained unchanged.
DISCUSSION
TAVI represents a less-invasive alternative to open sur-
gery indicated in the treatment of aortic stenosis in elderly
and high-risk patients.6,19 However, major concerns
remain, mainly related to the access route and ways to
optimize prosthesis implantation. In patients with
iliofemoral arteriopathy, transfemoral access may turn out
to be unfeasible or too high risk. The development of
narrower sheaths may not be the only solution to ensure
implantation success. When a transarterial route is not
accessible, a transapical approach may be an interesting
alternative in some patients.20 However, because the ap-
proach requires thoracotomy and left ventricular puncture,
it may not be suitable in fragile patients, especially in those
with severe respiratory or ventricular dysfunction. TheTABLE 2. Procedural outcome
Successful valvuloplasty 100%
Successful prosthesis implantation 100%
Death, intraprocedure 0
Stroke, minor 0
Cardiac perforation 0
Ventricular fibrillation 0
Emergency cardiac surgery 0
Transfusion rate  2 units 43%
Hospital stay (d) 9,4
Myocardial infarction 0%
rdiovascular Surgery c Volume 141, Number 2 489
TABLE 3. Postprocedural outcome (follow-up of 30 days)
Death 2 patients
Thromboembolism 0%
Transient ischemic attack 1 patient
Myocardial infarction 0%
Aortic dissection 1 patient
Tamponade 0%
Conversion to surgery 0%
NYHA class I and II 100%
endocarditis 0%
Values are n (%) unless otherwise stated. NYHA, New York Heart Association.
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cular surgeons. In comparison with the transfemoral ap-
proach, positioning the valve and controlling its release
proved considerably easier and offered greater movement
precision. The short distance between the subclavian artery
and the aortic annulus might explain a sense of increased
control of the delivery catheter and guide wire. The subcla-
vian and proximal axillary arteries are of good size and usu-
ally only moderately diseased even in the oldest population
groups. The vessels could be approached through an infra-
or a supraclavicular incision, especially in patients with
pacemakers implanted in the infraclavicular area to avoid in-
fective endocarditis risk. We used this route in 2 patients
with a history of pacemaker implantation. As in our routine
practice for transfemoral implantation, we did not use
transesophageal echocardiography control during valve po-
sitioning. We currently indicate a transesophageal echocar-
diography study in case of tamponade suspicion at the end
of the procedure.
Although the left subclavian artery is the preferred access
point, used in 15 of our 17 patients, the right subclavian ar-
tery21 has also been safely used in 2 patients. It is important
to note that for a right subclavian approach, the angle between
the aortic annulus plan and the horizontal line should no be
greater than 20 to 25 degrees to achieve a safe implantation.
This study reports a real-life prospective study of selected
high-risk patients with degenerative aortic valve stenosis
who were treated with TAVI using subclavian or axillary ac-
cess. The results of this prospective series of 17 patients, in
accordance with similar recently published articles, confirmTABLE 4. Echocardiographic characteristics
Baseline Postprocedure 1 mo
Gradient mm Hg, mean 47  13.3 7.9  4.1 7.9  4.1
Valve area,* cm2, mean  SD 0.6  0.3 1.44  0.35 1.44  0.35
Annulus diameter, mm,
mean  SD
27.2  5.5 NC NC
Aortic valve insufficiency,
grade  2
0% 20% 13.3%
Aortic paravalvular insufficiency,
grade  2
NA 20% 20%
SD, Standard deviation; NC, not calculated; N/A, not applicable. *Derived from con-
tinuity equation.
490 The Journal of Thoracic and Cardiovascular Surgthe feasibility of the procedure.18,19,22 Optimal positioning
of the prosthetic valve is mandatory to reduce risk of
embolization, paravalvular insufficiency, and coronary
obstruction. Because of the shorter distance between the
arterial entry point and the implantation site, when
compared with the femoral access, axillary or subclavian
access provides better sheath and delivery catheter
stability, increasing the accuracy of positioning the valve
and reducing procedure time. Moreover, subclavian
vascular repair was easily performed and surgical control
of the access point allowed for limited risk of immediate or
delayed vascular complications, as observed with the
percutaneous transfemoral access.
This approach is also feasible in patients with coronary ar-
tery bypass grafting history with a patent left internal tho-
racic artery or right internal thoracic artery bypass. In our
series, 2 patients with patent left and right internal thoracic
arteries received implants using the right subclavian access.
Nevertheless, this access route should be considered care-
fully in such situations because of the potential risk of sub-
clavian dissection that may compromise graft patency;19
a minimum artery diameter of 6.5 to 7 mm should be re-
quired. The transfusion rate in our series, in a population
with preoperative anemia, was high (43% of patients,  2
units), although no major bleeding complications occurred
throughout the study. Unlike in other reports that have re-
ferred to major bleeding or access site bleeding rates,23,24
which are difficult to evaluate and compare, we preferred
to calculate the transfusion rate allowing for a faithful
reflection of bleeding complication rates.
Although stroke is a known risk of routine balloon valvu-
loplasty,25,26 none of our patients experienced an ischemic
cerebrovascular event. However, 2 patients who underwent
operation via supraclavicular access experienced transitory
proximal neurologic deficits of the forearm secondary to
plexus brachial damage.
Severe (grade>2) paravalvular leak was not observed in
our series. Paravalvular leaks altogether were uncommon
and seemed to result from large calcifications positioned be-
tween the prosthesis and the annulus causing incomplete
sealing. Two patients required iterative balloon valvulo-
plasty inside the prosthesis, all during the same procedure
and using the same valvuloplasty balloon, to reduce para-
valvular leaks responsible for aortic regurgitation greater
than grade 2. In our study, the length of hospital stay was
relatively long. This can easily be explained by the degree
and severity of comorbidity of the study population at
higher risk than the population of patients who are usually
encountered in hospital practice. During follow-up, 2 pa-
tients died of noncardiovascular causes. Confirmation of
the efficacy and safety of this technique will require a larger
population. We believe the relative ease offered by the
transaxillary route compares favorably with our experience
of the transfemoral access, allowing more accuracy inery c February 2011
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Simplanting the valve and, as a result, lower average grades
of paravalvular leak.
CONCLUSIONS
Percutaneous aortic valve implantation is an emergent
technology with potential benefit in many patients. Current
application of this procedure is limited to patients who are
poor candidates for surgical valve replacement. Among
this aging population, a number of patients do not meet
the criteria for percutaneous transfemoral implantation be-
cause of the lack of suitable femoral arterial access. The
transaxillary or subclavian approach in patients with difficult
or unsuitable iliofemoral arteries represents a safe, feasible,
and technically interesting alternative.
The authors thank Dr Christopher Hurt for important collabora-
tion.
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FIGURE E1. Subclavian surgical access; 18F sheath insertion.
FIGURE E2. Surgical access closed.
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